It's been a mediocre week for ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shareholders, with the stock dropping 11% to...
ACADIA's Revenue Surges with Strong Sales from NUPLAZID and DAYBUE
ACADIA Pharmaceuticals ( NASDAQ:ACAD ) First Quarter 2024 Results Key Financial Results Revenue: US$205.8m (up 74% from...